{"id":"W2338387150","doi":"10.1200/jco.2009.27.15_suppl.8009","title":"Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Gastroenterology; Cancer; Epidermal growth factor receptor; Sorafenib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001022039,0.000248571,0.002633755,0.0001851385,0.00003760979,0.000008226235,0.0001300717,0.0003252414,0.0003640171],"category_scores_gemma":[0.0002067077,0.0001599966,0.0005554034,0.0002152304,0.0001629751,0.0001453198,0.00001958004,0.0006284663,0.000002169507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005218173,"about_ca_system_score_gemma":0.002208902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002495523,"about_ca_topic_score_gemma":0.0002659394,"domain_scores_codex":[0.9963142,0.0002096679,0.002450749,0.0002849483,0.0004363441,0.0003041129],"domain_scores_gemma":[0.9958616,0.0008540002,0.002238951,0.0002190268,0.0005012482,0.0003252044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.950812,0.01090597,0.01489788,0.00003755996,0.0009946054,0.0001037366,0.0005570777,0.00005160375,0.00009795053,0.000002708038,0.0001086929,0.02143024],"study_design_scores_gemma":[0.93892,0.03441374,0.02280854,0.0003512598,0.002270396,0.000006132037,0.0000597351,0.00002855252,0.0002567137,0.000007212304,0.0007347578,0.000142945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925293,0.0005184779,0.00009754177,0.001887212,0.0007827755,0.003298375,0.0000119884,0.000005967826,0.0008683559],"genre_scores_gemma":[0.9952002,0.0004026587,0.002747241,0.0006792875,0.0005863569,0.0001003469,0.00001435965,0.00002625072,0.000243308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02350777,"threshold_uncertainty_score":0.6524473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04300033028782617,"score_gpt":0.4350229883210954,"score_spread":0.3920226580332692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}